India Pharma Outlook Team | Monday, 16 June 2025
Under its BioE3 (Biotechnology for Economy, Environment, and Employment) policy, which aims to promote high-performance biomanufacturing, the Department of Biotechnology (DBT) intends to support the biomanufacturing of active pharmaceutical ingredients (APIs) and others in specific product strains with lower carbon emissions.By switching to less carbon-intensive biomanufacturing of chemicals, polymers, and APIs using sustainable bio-based feedstocks, the effort aims to decarbonize the chemical and pharmaceutical industries and lower greenhouse gas emissions.Proposals are being accepted for the biomanufacturing of bio-based chemicals, biopolymers, and APIs by DBT and the Biotechnology Industry Research Assistance Council (BIRAC). The biomanufacturing of these products will be green, environmentally friendly, and renewable alternatives to conventional chemicals, especially using indigenous production strains or strains with freedom of operation. Proposals must be submitted by July 31, 2025.
Following the completion of legal agreements and the payment of a one-time licensing fee, the chosen candidates would have access to approximately six product strains via the "BioE3 strain resource center for fostering high performance biomanufacturing" at the Biotechnology Research and Innovation Council (BRIC)-National Centre for Cell Science (NCCS), Pune.The Center's web portal provides access to the related information, such as the production strain catalog, user/depositor instructions, the agreement that needs to be completed, etc.
The biomanufacturing of penicillin G, 7-ACA, erythromycin thiocyanate, clavulanic acid, neomycin, gentamicin, betamethasone, dexamethasone, prednisolone, rifampicin, vitamin B1, clindamycin base, streptomycin, tetracycline, and lovastatin should be the primary focus of API proposals, though this is not the only one.
, CDSCO.jpg)
